Table 2.
Changes of biochemical, hormonal, and densitometric parameters in patients after 6 months of pulsatile gonadorelin treatment.
| Baseline | 6 mon. | P | |
|---|---|---|---|
| (n = 22) | (n = 22) | ||
| BMI (kg/m2) | 22.87 ± 4.06 | 24.6 ± 3.64 | 0.021 |
| FSH (mIU/mL) | 1.30 ± 1.04 | 5.14 ± 3.64 | 0.008 |
| LH (mIU/mL) | 0.81 ± 0.68 | 4.97 ± 3.50 | 0.002 |
| TT (nmol/L) | 0.78 ± 0.42 | 10.86 ± 7.68 | 0.002 |
| TC (mmol/L) | 4.63 ± 1.97 | 4.41 ± 1.81 | 0.034 |
| TG (mmol/L) | 1.61 ± 1.12 | 1.59 ± 0.84 | 0.980 |
| LDL-C (mmol/L) | 2.51 ± 0.94 | 2.68 ± 1.41 | 0.151 |
| HDL-C (mmol/L) | 1.46 ± 0.35 | 1.74 ± 0.71 | 0.956 |
| FBG (mmol/L) | 5.50 ± 0.52 | 5.58 ± 0.49 | 0.888 |
| Insulin (μIU/mL) | 22.38 ± 7.41 | 15.84 ± 5.15 | 0.025 |
| HOMA-IR | 5.31 ± 2.28 | 3.48 ± 1.77 | 0.021 |
| 25(OH)-Vitamin D (ng/mL) | 15.49 ± 4.65 | 17.76 ± 5.92 | 0.498 |
| SHBG (nmol/L) | 45.46 ± 14.00 | 16.42 ± 8.95 | 0.001 |
| L2 – 4 (g/cm2) | 0.905 ± 0.153 | 1.017 ± 0.143 | 0.002 |
| FN (g/cm2) | 0.802 ± 0.111 | 0.923 ± 0.101 | 0.003 |
| TH (g/cm2) | 0.838 ± 0.123 | 0.920 ± 0.117 | 0.003 |
BMI: body mass index; FSH: follicle-stimulating hormone; LH: luteinizing hormone; T: testosterone; TC: total cholesterol; TG: total triglyceride; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; FBG: fasting blood glucose; HOMA-IR: homeostasis model assessment of insulin resistance; SHBG: sex hormone-binding globulin; L2 – 4: lumbar spine 2–4; FN: femoral neck; TH: total hip.